NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: B3C Communications

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

B3C Newswire Named Official Newswire Partner of BIOTECHNICA 2010 for the International Trade Media - b3c newswire, the first PR distribution service completely dedicated to biotech, announces that BIOTECHNICA 2010 has chosen b3c newswire to be the official newswire partner for the international biotech and pharmaceutical trade media
B3C Newswire Named Official Newswire Partner of BIOTECHNICA 2010 for the International Trade Media

 

NewswireTODAY - /newswire/ - Traunstein, Germany, 2010/05/04 - b3c newswire, the first PR distribution service completely dedicated to biotech, announces that BIOTECHNICA 2010 has chosen b3c newswire to be the official newswire partner for the international biotech and pharmaceutical trade media.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“The reach in trade media and the quality of our hand-picked media titles are unrivaled. b3c newswire offers many specialized channels, a targeted biotech Twitter network and access to thousands of biotech professionals through social media to assure excellent visibility and awareness of news releases,” says Dr. Sabine Duntze from b3c newswire. “We are delighted to be the official newswire partner for BIOTECHNICA 2010 for the trade media worldwide.”

Main features of b3c newswire:

• Largest reach in biotech and pharmaceutical trade media worldwide;
• Many specialized channels;
• News is distributed according to the editors’ preferences for maximum awareness;
• News is indexed in Google News and Yahoo!;
• Access to a targeted biotech Twitter network;
• Reaches thousands of biotech professionals through social media.

About b3c newswire

b3c newswire (b3cnewswire.com) is the first PR distribution service completely dedicated to biotech. b3c newswire media network stands out for its quality and reach targeting print, online and social media for subjects related to biotechnology, pharmaceuticals, life sciences, or health care. In addition, b3c serves a targeted Twitter network for maximum visibility. Founded by a team of experienced biotech PR consultants with a life sciences background, b3c newswire combines PR and life science expertise.

About Biotechnica

BIOTECHNICA (biotechnica.de) is Europe’s leading annual event for biotechnology and the life sciences. It covers the entire spectrum of biotechnology, including fundamentals and equipment, bio-informatics and services, and addresses all five major fields of application, i.e. pharma-ceuticals/medicine, industrial manufacturing, food, agriculture and the environment. Ever since 1985, BIOTECHNICA has been organized and staged by Deutsche Messe AG in Hannover, Germany.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: B3C Communications

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


B3C Newswire Named Official Newswire Partner of BIOTECHNICA 2010 for the International Trade Media

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sabine Duntze - B3C.de 
+49 8619098220 info[.]b3cnewswire.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any B3C Communications securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From B3C Communications / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)